Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
- PMID: 36750526
- PMCID: PMC10088547
- DOI: 10.7570/jomes22067
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Abstract
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program. The SURPASS trials assessed the safety and efficacy of tirzepatide in people with T2DM, from monotherapy through to insulin add-on in global populations, with another two trials dedicated to Japanese population. Over periods of treatment up to 104 weeks, once weekly tirzepatide 5 to 15 mg reduced glycosylated hemoglobin (1.87% to 3.02%), body weight (5.4 to 12.9 kg) and improved multiple cardiometabolic risk factors (including reduction in liver fat, new-onset macroalbuminuria, blood pressure, and lipids) across the T2DM spectrum. Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine. All tirzepatide doses were well tolerated with similar side-effect profile to the GLP-1 receptor analogues. In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.
Keywords: Diabetes mellitus; Gastric inhibitory polypeptide; Glucagon-like peptide 1; Obesity; Tirzepatide; type 2.
Figures




Similar articles
-
Tirzepatide: A Review in Type 2 Diabetes.Drugs. 2024 Feb;84(2):227-238. doi: 10.1007/s40265-023-01992-4. Epub 2024 Feb 23. Drugs. 2024. PMID: 38388874 Review.
-
[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].Rev Med Liege. 2024 Dec;79(12):812-820. Rev Med Liege. 2024. PMID: 39697128 Review. French.
-
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond.Cureus. 2023 May 1;15(5):e38379. doi: 10.7759/cureus.38379. eCollection 2023 May. Cureus. 2023. PMID: 37265914 Free PMC article. Review.
-
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.Ann Pharmacother. 2023 Jul;57(7):822-836. doi: 10.1177/10600280221134127. Epub 2022 Nov 11. Ann Pharmacother. 2023. PMID: 36367094 Review.
-
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7. Cardiovasc Diabetol. 2022. PMID: 36050763 Free PMC article. Review.
Cited by
-
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2023 Oct 16;14:1214334. doi: 10.3389/fendo.2023.1214334. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37908750 Free PMC article.
-
Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Arch Endocrinol Metab. 2024 Nov 25;68:e240422. doi: 10.20945/2359-4292-2024-0422. eCollection 2024. Arch Endocrinol Metab. 2024. PMID: 39664998 Free PMC article. Review.
-
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.Biomedicines. 2024 Jun 13;12(6):1320. doi: 10.3390/biomedicines12061320. Biomedicines. 2024. PMID: 38927527 Free PMC article. Review.
-
Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.J Diabetes Investig. 2025 May;16(5):807-816. doi: 10.1111/jdi.14395. Epub 2025 Feb 1. J Diabetes Investig. 2025. PMID: 39891527 Free PMC article. Clinical Trial.
-
Obesity medications: A narrative review of current and emerging agents.Osteoarthr Cartil Open. 2024 Apr 25;6(2):100472. doi: 10.1016/j.ocarto.2024.100472. eCollection 2024 Jun. Osteoarthr Cartil Open. 2024. PMID: 38737985 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources